FDA Releases Draft Guidance on Forms 3542a and 3542 for Labeling Submissions

Regulatory affairs teams managing labeling submissions now have a formal Q&A reference point: FDA's Center for Drug Evaluation and Research (CDER) has released a draft guidance titled Forms FDA 3542a and FDA 3542: Questions and Answers, published under docket number FDA-2026-D-2698. The document is designed to clarify how applicants should prepare and submit these forms, which govern promotional labeling and advertising submissions to the Agency.

Forms 3542a and 3542 are required when sponsors submit promotional materials for FDA review. Misaligned or incomplete submissions on these forms have historically triggered back-and-forth with CDER reviewers, extending review timelines. The new draft guidance consolidates commonly asked questions into a single reference, giving submissions teams a clearer procedural baseline ahead of any formal comment resolution.

Under 21 CFR 10.115(g)(5), comments on draft guidance may be submitted at any time, online or in writing. Written submissions should be directed to the Dockets Management office at 5630 Fishers Lane, Rm 1061, Rockville, MD 20852, with the docket number FDA-2026-D-2698 clearly identified. Regulatory leads who identify gaps between current internal submission practices and the clarifications outlined in this draft should document those gaps now, before the guidance is finalized.

For QA directors and regulatory operations leads, the practical read is straightforward: this is an opportunity to audit existing form-completion workflows against the Q&A framework CDER has now made explicit. Teams that have relied on informal interpretations or legacy submission templates should treat this draft as a signal to reconcile those practices with the Agency's stated expectations.

Finalization of the guidance will establish the Q&A document as the authoritative procedural reference for 3542a and 3542 submissions across all drug applicants interfacing with CDER's promotional review process.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Guidance Documents, June 12, 2026. Docket: FDA-2026-D-2698.